Priyanka Sharma
A5049107000- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Ovarian cancer diagnosis and treatment
- Cancer Cells and Metastasis
- DNA Repair Mechanisms
- PARP inhibition in cancer therapy
- Genetic Associations and Epidemiology
- Breast Lesions and Carcinomas
- PI3K/AKT/mTOR signaling in cancer
- Estrogen and related hormone effects
- Molecular Biology Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Immunotherapy and Immune Responses
- Cancer-related molecular mechanisms research
- Cancer-related Molecular Pathways
- SARS-CoV-2 and COVID-19 Research
- Genetic factors in colorectal cancer
- Genomics and Chromatin Dynamics
- Cancer Research and Treatments
- Genomic variations and chromosomal abnormalities
University of Kansas Medical Center
2016-2025
Manipal Academy of Higher Education
2025
The University of Kansas Cancer Center
2009-2025
Employees' State Insurance Model Hospital
2024
Career Point University
2024
University of Kansas
2007-2024
Rutgers Sexual and Reproductive Health and Rights
2024
Central University of Punjab
2024
Maharshi Dayanand University
2024
Rutgers, The State University of New Jersey
2024
Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing patients. We assessed frequency mutations 17 predisposition genes, including BRCA1 and BRCA2, a large cohort patients with triple-negative (TNBC) unselected family history or ovarian determine utility those TNBC. Patients Methods TNBC (N = 1,824) were recruited through 12 studies, was sequenced identify mutations. Results Deleterious identified 14.6%...
The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary lymph-node-negative breast cancer. In women with positive lymph-node disease, role of respect to adjuvant is unclear.In prospective trial, we randomly assigned HER2-negative cancer, one three lymph nodes, and 25 or lower (scores range from 0 100, higher scores indicating...
BackgroundPrevious studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate relationship RCB with long-term prognosis across different phenotypic subtypes breast cancer, assess generalisability broad range practice settings.MethodsIn this analysis, 12 institutes and trials Europe USA were identified by personal communications...
Germline genetic testing with hereditary cancer gene panels can identify women at increased risk of breast cancer. However, those triple-negative (estrogen receptor–negative, progesterone human epidermal growth factor receptor–negative) (TNBC) cannot be identified because predisposition genes for TNBC, other than BRCA1, have not been established. The aim this study was to define the panel associated TNBC. Multigene 21 in 8753 TNBC patients performed by a clinical laboratory, and 17 2148...
The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti-Trop-2) antibody-drug conjugate linked the topoisomerase-inhibitor SN-38, over single-agent chemotherapy treatment of physician's choice (TPC) in previously treated metastatic triple-negative breast cancer (mTNBC). This prespecified, exploratory biomarker analysis from evaluates association between tumor Trop-2 expression and...
Addition of pembrolizumab to anthracycline-based chemotherapy improves pathologic complete response (pCR) and event-free survival (EFS) in triple-negative breast cancer (TNBC). The efficacy anthracycline-free chemoimmunotherapy TNBC has not been assessed.
Abstract Background CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have a well-established role the management of hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). The benefit continuing CDK4/6i beyond progression different ET has not been confirmed. Preclinical data suggest synergy between and PD-L1 inhibition. PACE trial prospectively evaluates whether continuation CKD4/6i palbociclib on prior aromatase inhibitor (AI), change to fulvestrant,...
Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), but it is not known if patients might derive benefit from continuation CDK4/6i with endocrine therapy beyond initial tumor progression or the addition checkpoint inhibitor has value in this setting.
ASCO Rapid Recommendation Updates highlight revisions to select guideline recommendations as a response the emergence of new and practice-changing data. The rapid updates are supported by an evidence review follow development processes outlined in Guideline Methodology Manual. goal these articles is disseminate updated recommendations, timely manner, better inform health practitioners public on best available cancer care options. Guidelines not intended substitute for independent...
Triple-negative (TN) breast cancer is an aggressive subtype of associated with a unique set epidemiologic and genetic risk factors. We conducted two-stage genome-wide association study TN (stage 1: 1529 cases, 3399 controls; stage 2: 2148 1309 controls) to identify loci that influence risk. Variants in the 19p13.1 PTHLH showed significant associations (P < 5 × 10−8) 1 2 combined. Results also suggested substantial enrichment significantly variants among single nucleotide polymorphisms (SNPs)...
Abstract Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness anthracycline-free platinum combinations TNBC is not well known. Here, we report efficacy NA + docetaxel (CbD) TNBC. Experimental Design: The study population includes 190 patients with stage I–III treated uniformly on two independent prospective cohorts. All were...
Abstract Purpose: Prognostic value of pathologic complete response (pCR) and extent attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) overall (OS) according to degree patients treated carboplatin docetaxel NAC. Patients Methods: One-hundred ninety stage I–III TNBC were (AUC6) (75 mg/m2) every 21 days × 6 cycles. pCR (no evidence invasive tumor axilla) Residual...
BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity data exists on the pathology cancers (BCs) in men BRCA1/2 mutations. Using largest available dataset, we determined whether MBCs arising mutation carriers display specific pathologic features and these differ from those female BCs (FBCs). We characterised 419 using logistic regression analysis, contrasted 9675 FBCs population-based 6351 Surveillance, Epidemiology,...
Abstract Funding: Supported by National Cancer Institute grants U10CA180888, U10CA180819, U10CA180820, U10CA180821, U10CA180868, U10CA180863; and in part Susan G. Komen for the Cure® Research Program, The Hope Foundation Research, Breast Foundation, Genomic Health, Inc. Acknowledgement: authors wish to thank Dr. Ana M. Gonzalez-Angulo, MD, her invaluable contributions design implementation of this study. Background: clinical utility RS determine CT benefit is well established pts with HR+,...
Abstract Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim the NeoSTOP multisite randomized phase II trial was assess efficacy anthracycline-free anthracycline-containing neoadjuvant regimens. Patients Methods: aged ≥18 years with stage I–III TNBC were (1:1) receive either paclitaxel (P) weekly × 12 AUC6 every 21 days 4 followed...
Abstract Purpose: PIK3CA mutations are common in breast cancer and promote tumor progression treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel patients with HER2-negative metastatic (MBC). Patients Methods: Eligible had MBC any number prior chemotherapies. Phase I was 3+3 dose-escalation design three dose levels (250, 300, 350 mg) daily 100 mg/m2 administered on days 1, 8, 15 every 28 days. II according to Simon's two-stage...
513 Background: Addition of pembrolizumab to anthracycline-taxane-platinum chemotherapy improves pathologic complete response (pCR) and event free survival (EFS) in TNBC. Aim this study was assess the efficacy anthracycline neoadjuvant regimen plus carboplatin docetaxel (Cb+D) Methods: In multicenter study, eligible patients with stage I-III TNBC received (AUC 6) + (75 mg/m 2 ) (200 mg) every 21 days x 6 cycles. The primary endpoint pCR (no evidence invasive tumor breast axilla). Secondary...
Triple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone (PR) immunohistochemistry expression <1% absence of HER2 amplification/overexpression. HER2-negative with low ER/PR (1-10%) has a gene profile similar to TNBC; however, real-world treatment patterns, chemotherapy response, endocrine therapy benefit, survival outcomes for the Low-ER group are not well known. 516 patients stage I-III ≤10% who were enrolled in multisite prospective registry...
Abstract Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify RD could help individualize adjuvant and inform future trials. We aim investigate the impact of circulating tumor DNA (ctDNA) status burden (RCB) class on outcomes in TNBC RD. analyze end-of-treatment ctDNA 80 who enrolled a prospective multisite registry. Among patients, 33% positive (ctDNA+) RCB distribution...